We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current 0NWK market cap is 142.62M. The company's latest EPS is EUR -0.1754 and P/E is -7.30.
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 12.59M | 5.33M | 16.13M | 5.85M | 3.4M |
| Operating Income | -10.47M | -9.83M | 2.22M | -5.14M | -16.73M |
| Net Income | -9.4M | -33.73M | 1.09M | -5.94M | -19.56M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 63.25M | 37.63M | 46.51M | 53.06M | 43.09M |
| Total Liabilities | 17.85M | 20.43M | 17.47M | 20.12M | 20.82M |
| Total Equity | 45.4M | 17.2M | 29.04M | 32.94M | 22.27M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -11.27M | -7.7M | -4.68M | -8.57M | -9.44M |
| Investing | 1,000 | 137k | 6.02M | -66k | -409k |
| Financing | 8.25M | 2.01M | 7.48M | 11.98M | 6.46M |
| Market Cap | 142.62M |
| Price to Earnings Ratio | -7.30 |
| Price to Sales Ratio | 41.97 |
| Price to Cash Ratio | 9.79 |
| Price to Book Ratio | 6.41 |
| Dividend Yield | - |
| Shares Outstanding | 111.51M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.00% |
| 52 Week High | 1.279 |
| 52 Week Low | 1.279 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Valerio Therapeutics |
| Address |
49 boulevard du general martial valin paris, paris 75015 |
| Website | https://www.onxeo.com |
| Industry | medicinal chems,botanicl pds (2833) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
